AYTU BIOPHARMA, INC 8-K

What Happened

• Aytu BioPharma, Inc. (AYTU) filed an 8-K reporting that on March 31, 2026 it amended warrants issued in June 2023 and June 2025 to remove ambiguity in stockholder/ownership “blocker” language. The company canceled the previously issued instruments and issued (i) an Amended 2023 Prefunded Warrant, (ii) an Amended 2023 Tranche A Warrant and (iii) an Amended 2025 Prefunded Warrant.
• During preparation of its 2025 quarterly reports, Aytu determined that the prior blocker language created accounting ambiguity under ASC Topic 480 and ASC Topic 815, which led to classifying the warrants as liabilities. As a result it recorded a warrant liability of $18.1 million for the quarter ended September 30, 2025 and $25.2 million for the quarter ended December 31, 2025.

Key Details

• Amendment date: March 31, 2026; three warrant forms were amended and reissued (2023 prefunded, 2023 Tranche A, 2025 prefunded).
• The amendments clarify that the company’s stockholders cannot vote to amend or change the ownership/blocker provisions.
• Prior accounting impact: $18.1M liability recorded in Q3 2025 and $25.2M in Q4 2025 due to liability classification of the original warrants.
• Company expectation: following the amendments, the warrant liability on the financial statements will be reduced and equity will increase by that same amount.

Why It Matters

• This is an accounting-terms change intended to correct an unintended liability classification for the warrants. If the amendments achieve equity classification as expected, Aytu’s balance sheet will show a lower liability and correspondingly higher equity, which can affect financial ratios and reported equity value.
• The change stems from authoritative accounting guidance (ASC 480 and ASC 815) and is material because the previously recorded warrant liabilities were in the tens of millions. Investors should watch Aytu’s upcoming financial reports (10-Qs/10-K) for the formal restatement or presentation of the revised warrant accounting and to see the exact impact on reported results.